| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 39, 181-195, Copyright © 1993 by American Association for Clinical Chemistry
DA Armbruster
Analytical Sciences Branch, US Air Force Drug Testing Laboratory, Brooks Air Force Base, TX 78235.
Prostate-specific antigen (PSA) is a glycoprotein produced exclusively by prostatic tissue. PSA's absolute tissue specificity makes it valuable as a forensic marker and, more important, as a tumor marker for prostatic cancer. Prostatic cancer is prevalent in the older male population and is a major cause of death in men. Previously, prostatic acid phosphatase (PAP) was used to help diagnose and monitor the efficacy of therapy for prostate cancer. PAP has now been displaced by PSA, which has greater clinical sensitivity even though it has less clinical specificity. PSA is useful for monitoring therapy, particularly surgical prostatectomy, because complete removal of the prostate gland should result in PSA being undetectable. Measurable PSA after radical prostatectomy indicates residual prostatic tissue or metastasis, and increasing PSA concentrations indicate recurrent disease. PSA is also useful for screening selected populations of patients with symptoms indicative of prostate cancer; its use for general screening is debatable because of its less-than-optimal specificity, the cost of unselected screening, and the lack of evidence that early detection of prostate cancer decreases morbidity and mortality. Distinguishing between patients with prostatic cancer and those with benign prostatic hypertrophy is particularly difficult because of the overlap in PSA values in the two groups. Determining the rate of change in PSA per year from serial measurements or calculating the ratio of PSA per volume of the prostate gland may allow these two groups to be more readily differentiated.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  S. A.R. Kort, F. Martens, H. Vanpoucke, H. L. van Duijnhoven, and M. A. Blankenstein Comparison of 6 Automated Assays for Total and Free Prostate-Specific Antigen with Special Reference to Their Reactivity toward the WHO 96/670 Reference Preparation Clin. Chem., August 1, 2006; 52(8): 1568 - 1574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Grzeda, T. Le Bui, C. N. Warner, T. L. Pirucki, L. M. Dewey, M. Babich, and J. A. Maggiore Measurement of Prostate-specific Antigen by Use of a Novel Blood Collection and Analytical System Clin. Chem., August 1, 2002; 48(8): 1272 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Aksoy, F. Akcay, Z. Umudum, A. K. Yildirim, and R. Memisogullari Changes of PSA Concentrations in Serum and Saliva of Healthy Women during the Menstrual Cycle Ann. Clin. Lab. Sci., January 1, 2002; 32(1): 31 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Black, M. Giai, R. Ponzone, P. Sismondi, H. Yu, and E. P. Diamandis Serum Total and Free Prostate-specific Antigen for Breast Cancer Diagnosis in Women Clin. Cancer Res., February 1, 2000; 6(2): 467 - 473. [Abstract] [Full Text]
|
|
|
|
|
|
F. Mannello, M. Malatesta, M. Sebastiani, S. Battistelli, and G. Gazzanelli Molecular Forms and Ultrastructural Localization of Prostate-specific Antigen in Nipple Aspirate Fluids, Clin. Chem., December 1, 1999; 45(12): 2263 - 2266. [Full Text] [PDF]
|
|
|
|
|
|
N. H.L. Chiu and T. K. Christopoulos Two-Site Expression Immunoassay Using a Firefly Luciferase-coding DNA Label Clin. Chem., November 1, 1999; 45(11): 1954 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Bidart, F. Thuillier, C. Augereau, J. Chalas, A. Daver, N. Jacob, F. Labrousse, and H. Voitot Kinetics of Serum Tumor Marker Concentrations and Usefulness in Clinical Monitoring Clin. Chem., October 1, 1999; 45(10): 1695 - 1707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nagasaki, M. Watanabe, N. Komatsu, T. Kaneko, J. Y. Dube, T. Kajita, Y. Saitoh, and Y. Ohta Epitope Analysis of a Prostate-specific Antigen (PSA) C-Terminal-specific Monoclonal Antibody and New Aspects for the Discrepancy between Equimolar and Skewed PSA Assays Clin. Chem., April 1, 1999; 45(4): 486 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Black, C. L. Grass, J. Leinonen, U.-H. Stenman, and E. P. Diamandis Characterization of Monoclonal Antibodies for Prostate-specific Antigen and Development of Highly Sensitive Free Prostate-specific Antigen Assays Clin. Chem., March 1, 1999; 45(3): 347 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mannello, M. Malatesta, F. Luchetti, S. Papa, S. Battistelli, and G. Gazzanelli Immunoreactivity, Ultrastructural Localization, and Transcript Expression of Prostate-specific Antigen in Human Neuroblastoma Cell Lines Clin. Chem., January 1, 1999; 45(1): 78 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lopez-Otin and E. P. Diamandis Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features Endocr. Rev., August 1, 1998; 19(4): 365 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mannello, M. Malatesta, E. Fusco, G. Bianchi, A. Cardinali, and G. Gazzanelli Biochemical Characterization and Immunolocalization of Prostate-specific Antigen in Human Term Placenta Clin. Chem., August 1, 1998; 44(8): 1735 - 1737. [Full Text] [PDF]
|
|
|
|
|
|
K. Jung, P. von Klinggraff, B. Brux, P. Sinha, D. Schnorr, and S. A. Loening Preanalytical Determinants of Total and Free Prostate-Specific Antigen and Their Ratio: Blood Collection and Storage Conditions Clin. Chem., March 1, 1998; 44(3): 685 - 688. [Full Text] [PDF]
|
|
|
|
|
|
G. M. Lambert-Messerlian, J. A. Canick, D. N. Melegos, and E. P. Diamandis Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down syndrome Clin. Chem., February 1, 1998; 44(2): 205 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Zucchelli, A. Pilo, M. R. Chiesa, R. Cohen, and Ch. A. Bizollon Analytical Performance of Free PSA Immunoassays: Results from an Interlaboratory Survey, Clin. Chem., December 1, 1997; 43(12): 2426 - 2428. [Full Text]
|
|
|
|
|
|
F. Mannello, M. Sebastiani, S. Amati, and G. Gazzanelli Prostate-specific antigen expression in a case of intracystic carcinoma of the breast: characterization of immunoreactive protein and literature surveys Clin. Chem., August 1, 1997; 43(8): 1448 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-F. Chen, Y. Xu, and M. P.-C. Ip Electrochemical Enzyme Immunoassay for Serum Prostate-Specific Antigen at Low Concentrations Clin. Chem., August 1, 1997; 43(8): 1459 - 1461. [Full Text]
|
|
|
|
|
|
F. Mannello, G. Miragoli, G. Bianchi, and G. Gazzanelli Prostate-Specific Antigen in Ascitic Fluid Clin. Chem., August 1, 1997; 43(8): 1461 - 1462. [Full Text]
|
|
|
|
|
|
F. Mannello, G. Miragoli, G. Bianchi, and G. Gazzanelli Immunoreactive Prostate-Specific Antigen in Pleural Effusions Clin. Chem., May 1, 1997; 43(5): 847 - 848. [Full Text]
|
|
|
|
|
|
F. T. Kreutz and M. R. Suresh Novel bispecific immunoprobe for rapid and sensitive detection of prostate-specific antigen Clin. Chem., April 1, 1997; 43(4): 649 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yu, E. P. Diamandis, M. Monne, and C. M. Croce Oral Contraceptive-induced Expression of Prostate-specific Antigen in the Female Breast J. Biol. Chem., March 24, 1995; 270(12): 6615 - 6618. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
